Develops personalized bio-engineered skin tissue therapies using automated bioreactor systems to produce de novo skin for patients with large skin injuries and defects. This approach addresses the limitations of traditional skin grafts by providing scalable, cost-effective, and customizable solutions for reconstructive surgery.
Funding
$97.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with large skin injuries and defects, such as those resulting from burns or trauma, often face limitations with traditional skin grafts, including a scarcity of donor skin, scarring at the donor site, and the potential need for follow-up corrective surgeries. Current wound closure options, like cultured epithelial autografts, consist of only the upper layer of the skin, which limits growth over time and causes increased scarring.
Solution
Cutiss AG is a TechBio company focused on regenerative medicine, offering personalized bio-engineered skin tissue therapies for reconstructive surgery. Their lead product, denovoSkin™, is a dermo-epidermal skin graft created from a small biopsy of the patient’s healthy skin, expanded to produce large quantities of new skin. This approach reduces the need for healthy skin harvesting, minimizes scarring, and decreases the necessity for subsequent corrective surgeries. The company has also developed an automated platform for scalable production of personalized tissue therapy, enabling decentralized production and cost-effective scale-up.
Target Audience
The primary target audience includes patients with extensive skin injuries or defects requiring reconstructive surgery, burn victims with limited donor sites, and surgeons seeking advanced solutions for improved patient outcomes and reduced scarring.
Features
- Personalized dermo-epidermal skin graft bio-engineered from the patient's own skin cells
- Scalable production of large quantities of skin from a small biopsy
- Automated bioreactor systems for efficient and cost-effective tissue engineering
- GMP-certified facility for clinical-grade manufacturing
- Reduces the need for extensive harvesting of healthy skin
- Designed to minimize scarring and improve functional outcomes
- Proprietary tissue engineering technology addressing limitations of current skin grafting methods
- Suitable for both burn and reconstructive skin surgery